Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

HUTCHMED Introduces Novel Fruquintinib in Combination with Sintilimab for Advanced Endometrial Cancer

HUTCHMED has introduced novel fruquintinib and sintilimab (a PD-1 antibody). The combination of fruquintinib and sintilimab is a promising development for patients with advanced endometrial cancer with pMMR1 tumours who have failed at least one line of platinum-based therapy. 

Fruquintinib is an oral inhibitor that specifically targets vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3. VEGFR inhibitors are essential in blocking tumour angiogenesis.

Fruquintinib is aimed to improve kinase selectivity, minimising off-target toxicities, and enhancing tolerability while providing consistent target coverage. It has shown good tolerability in patients and is being studied in combination with other anti-cancer therapies.

On the other hand, sintilimab is classified as an immunoglobulin G4 monoclonal antibody that specifically targets PD-1 molecules found on T-cells' surfaces. By blocking the PD-1/PD-Ligand 1 (PD-L1) pathway, it reactivates T-cells to attack cancer cells.

The breakthrough therapy designation (BTD) granted by China's National Medical Products Administration (NMPA) signifies the potential of this combination in treating advanced endometrial cancer patients.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024